Both ApoB and non-HDL-C are also recommended to improve ASCVD risk assessment, particularly in situations where discordance between these measures and LDL-C may occur (e.g. diabetes mellitus, obesity, metabolic syndrome, high TGs, and very low LDL-C levels). This evidence concerns the gene APOB and diabetes mellitus.